Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CG Oncology, Inc. (CGON : NSDQ)

• Company Description    CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif. Number of Employees: 113

• Price / Volume Information    Yesterday's Closing Price: $27.11 Daily Weekly Monthly 20 Day Moving Average: 749,184 shares Shares Outstanding: 76.22 (millions) Market Capitalization: $2,066.47 (millions) Beta: 0.86 52 Week High: $40.47 52 Week Low: $14.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.30% -1.53% 12 Week 31.35% 10.48% Year To Date -5.47% -11.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 SPECTRUM CENTER DRIVE SUITE 2040 - IRVINE,CA 92618 USA ph: 949-409-3700 fax: - ir@cgoncology.com https://cgoncology.com

• General Corporate Information    Officers Arthur Kuan - Chief Executive Officer and Chairman Corleen Roche - Chief Financial Officer Susan Graf - Director Brian Liu - Director James J. Mule - Director Peer Information CG Oncology, Inc. (CORR.) CG Oncology, Inc. (RSPI) CG Oncology, Inc. (CGXP) CG Oncology, Inc. (BGEN) CG Oncology, Inc. (GTBP) CG Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 156944100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 76.22 Most Recent Split Date: (:1) Beta: 0.86 Market Capitalization: $2,066.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 36.55% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.93 Price/Cash Flow: - Price / Sales: 3,121.54 EPS Growth vs. Year Ago Period: -25.00% vs. Previous Quarter: 6.25% Sales Growth vs. Year Ago Period: -90.17% vs. Previous Quarter: -88.60% ROE 06/30/25 - - 03/31/25 - -16.71 12/31/24 - -14.73 ROA 06/30/25 - - 03/31/25 - -16.24 12/31/24 - -14.37 Current Ratio 06/30/25 - - 03/31/25 - 30.97 12/31/24 - 35.30 Quick Ratio 06/30/25 - - 03/31/25 - 30.97 12/31/24 - 35.30 Operating Margin 06/30/25 - - 03/31/25 - -15,945.17 12/31/24 - -7,729.32 Net Margin 06/30/25 - - 03/31/25 - -15,945.17 12/31/24 - -7,729.32 Pre-Tax Margin 06/30/25 - - 03/31/25 - -15,945.17 12/31/24 - -7,729.50 Book Value 06/30/25 - - 03/31/25 - 9.25 12/31/24 - 9.63 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©